Memorandum of Understanding
Between The Food and Drug Administration
and The Indian Health Service
The Food and Drug Administration (FDA) and the Indian Health Service (IHS), U.S. Department of Health and Human Services (DHHS), have mutual interests in fostering improved health care and access to policy and education programs.
FDA and IHS intend to work to develop a more cohesive relationship to mutually address American Indian and Alaska Native issues within the context of each organization's jurisdiction. FDA and IHS agree to work together to promote and support appropriate ongoing DHHS and organizationally specific initiatives, such as:
Collaborative Tribal Consultations
-- National Congress of American Indians
-- National Indian Health Board
-- Regional Health Boards
The White House Initiative on Tribal Colleges and Universities
Expert Technical Assistance
Collaborative Public Health Education Campaigns
-- Clinical Trials and Education
-- Women's Health Issues – (Urban and Rural)
-- "Take Time to Care" Campaign
-- Food Labeling Education
-- Food/Nutrient/Deficiency/Food supplementation issues for women of child bearing age and health professionals
-- Food Safety Initiative
-- Health Fraud
Collaborative Consumer Studies
This MOU establishes policies and principles by which the parties may be guided when executing specific interagency agreements for the exchange of funds, services, or personnel.
Food and Drug Administration: Section 903 of the FFDCA (21 U.S.C. 393), Section 301 of the PHSA, (42 U.S.C. 241), Sections 1701 et seq. of the PHSA (42 U.S.C. 300u et seq.)
Indian Health Service: Transfer Act (42 U.S.C. 2001) of 1954.
The FDA and the IHS have been independently conducting activities, in the context of their jurisdictions, to improve the knowledge base of American Indian and Alaska Native populations and to involve these individuals in their respective processes. The FDA and the IHS recognized that the success of those efforts can be enhanced by greater collaboration.
The IHS has focused its outreach activities primarily on the needs of American Indian and Alaska Native populations. Similarly, the FDA has focused its efforts primarily upon the needs of the general population with intermittent emphasis upon American Indian and Alaska Native populations.
The goal of the FDA and the IHS collaborations will be to accomplish the following:
(1) More effectively interface with the IHS, the National Indian Health Board, the National Congress of American Indians, Regional Health Boards, and other DHHS components by:
--soliciting tribal advice and recommendations on approaches to achieve appropriate levels of effective and efficient involvement of American Indians and Alaska Natives in the FDA's regulatory and outreach processes;
--Enhancing local consultations and collaborations with tribal governments, when appropriate;
--receiving assistance in improving involvement of American Indians and Alaska Natives in Agency policy initiatives;
--discussing collaborative approaches to promote the safe and practical use of FDA-regulated products among American Indian and Alaska Native populations;
--discussing approaches and establishing distribution systems for materials through IHS Tribal and Urban Indian Health Programs, Indian schools, community colleges and universities, IHS Medical Centers and the Department of Veterans Affairs' regional medical centers;
(2) Improve access of American Indians and Alaska Natives to FDA generated information on health risks and policy issues;
(3) provide community based organizations and concerned individuals with the opportunities to have appropriate input into regulatory processes such as;
--encourage participation of American Indians and Alaska Natives in Agency-sponsored conferences, meetings, focus groups, and consumer studies;
--promote opportunities to serve on the FDA's advisory committees and panels, science boards, and in research;
(4) provide FDA and IHS officials and managers with the perspectives on America Indian and Alaska Native health care and education needs and policy issues;
(5) promote diversity in the planning and application of existing educational programs and services that encourage youth to pursue careers in the sciences, math, and other disciplines that may lead to careers in the advanced sciences, engineering and the health professions; and
(6) continue recruitment efforts to American Indian and Alaska Native populations through programs such as the Cooperative Education Programs (CO-OP), Commissioned Officer Student Training and Extern Program (COSTEP), fellowships, personnel exchanges, and summer employment programs through Tribal Colleges and Universities and professional associations.
IV. SCOPE OF WORK
The FDA and the IHS hereby express their firm intentions to jointly address American Indian and Alaska Native issues within the context of regulatory processes and programs conducted by the FDA primarily for the general U.S. population, as resources permit. Given the diversity of education, knowledge, understanding and cultures within the American Indian and Alaska Native populations, the IHS will work with FDA to enhance its activities with American Indian and Alaska Native populations.
FDA and IHS have established formal liaisons for both Agencies that will foster an information exchange on all aspects of the MOU. Other functions of the Agency liaisons may include the following:
Work with intra/inter-agency task groups to identify the type of technical assistance and outreach necessary to provide American Indian and Alaska Native populations with information and education.
Exchange information on currently funded programs that have objectives to address the health education needs of American Indian and Alaska Native populations.
Review opportunities for mutual and flexible funding and cooperative extension of funded programs for American Indian and Alaska Native populations through FDA and IHS grant programs.
Strengthen mutual cooperative activities and technical support in working with other DHHS components in developing resources to collect improved statistics on American Indian and Alaska Native populations.
V. DURATION OF AGREEMENT
This MOU will become effective upon acceptance by both parties and will continue in effect indefinitely. This MOU may be modified by mutual written consent or terminated by either party upon 60 day advance notice to the other party.
VI. LIAISONS/PROJECT OFFICERS
INDIAN HEALTH SERVICE
Approved and Accepted
for the Indian Health Service
Signed by: Director, Indian Health Service
Date: July 9, 1997
Approved and Accepted
for the Food and Drug Administration
Signed by: Lead Deputy Commissioner
Food and Drug Administration
Date: July 9, 1997